An expert discussed the screening and treatment of sarcoidosis and drug-induced sarcoidosis-like reactions during the 2021 ACR State-of-the-Art Clinical Symposium.


An expert discussed the screening and treatment of sarcoidosis and drug-induced sarcoidosis-like reactions during the 2021 ACR State-of-the-Art Clinical Symposium.

Advancements in the treatment of myositis are on their way, according to Hector Chenoy, PhD, FRCP, who outlined the latest clinical trials during the 2021 ACR State-of-the-Art Clinical Symposium.

Vania Lin, MD, MPH, Robert Odrobina, MD, Maria A. Pletneva, MD, PhD, & Dorota Lebiedz-Odrobina, MD, RhMSUS |
Common variable immunodeficiency (CVID) is a common primary immunodeficiency disease, with an estimated incidence of one per 25,000–50,000 individuals.1 The classic presentation includes frequent bacterial infections, secondary to dysfunctional B cell differentiation, impaired immunoglobulin production and diminished antibody response. The clinical presentation may be heterogenous and may include granulomatous disease as an uncommon manifestation. Granulomatous…

Devin M. Driscoll, MD, Andreea M. Bujor, MD, PhD, & Eugene Y. Kissin, MD, Rhmsus |
A 51-year-old man with a history of limited systemic sclerosis with Raynaud’s phenomenon and pulmonary hypertension being treated with tadalafil and macitentan presented to a clinic with ulceration of his right pinkie. The patient had injured the finger two months earlier. He reported poor healing and the presence of a persistent ulcer since the injury….

Barrett Ford, MD, Chandana Shilpa Ravipati, DO, & Nirupa Patel, MD |
Dermatomyositis (DM) is an idiopathic inflammatory myopathy involving proximal muscle weakness and skin rash. An associated increased risk of malignancy is well established.1 The most frequent malignancies are related to the ovary, endometrium, lung, gastrointestinal tract, prostate, breast and lymphatics.2 On rare occasions, DM has been reported with certain types of non-Hodgkin’s lymphoma, specifically cutaneous…

NIH investigators describe key features and genetic causes of Mendelian interferonopathies, & treatment approaches that may indicate the efficacy of IFN inhibition.

Shubhasree Banerjee, MD, & Peter A. Merkel, MD, MPH |
It is an exciting time in the world of vasculitis research. More clinical studies and trials are being conducted now than at any time in history. In the past ten years, four drugs have been approved by the U.S. Food & Drug Administration (FDA) and other regulatory agencies specifically for the treatment of vasculitis: Rituximab…

Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.

ACR Convergence panelists discussed how to monitor SSc-ILD patients for ILD severity & the brightening prospects for therapy.

During ACR Convergence 2020 in early November, the ACR and ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARP Merit Awards and the ACR’s Distinguished Fellows. In addition, we bring you the first ever…